The Board of Afon Technology is pleased to announce that it has raised £600,000 from a confidential investor to fund further miniaturisation of their medical device and take it into the manufacturing stage.
Afon Technology has the single focus of commercialising a wearable, non-invasive blood glucose monitor to benefit people with diabetes the world over.
Based on proven and patented technology, they have created a non-invasive, real-time and continuous glucose sensor that will empower people with diabetes in self-management and provide their clinicians with a history of their blood glucose variations.
The compact device is designed to be worn with a watchstrap and connected via Bluetooth to the user’s smart watch/device.
The device created gives individuals’ freedom from the constraints of conventional finger-stick devices.
Sabih Chaudhry, CEO of Afon Technology said, “We are delighted to have this confidential investor on board, as we pursue the development and clinical trials of the device. The technology is proving reliable and accurate in our initial trials, and we are excited by these results.”
Clive Hyman said, “We are glad to be working with Afon Technology, who are a leader in the next generation of wearable blood glucose monitoring devices. We have supported their investor through his decision process.”
For more information, please visit www.afontechnology.com
